ProQR Therapeutics (PRQR) Receives News Sentiment Score of 0.21

Headlines about ProQR Therapeutics (NASDAQ:PRQR) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. ProQR Therapeutics earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.7350404535471 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

ProQR Therapeutics (NASDAQ PRQR) traded up $0.10 during trading hours on Tuesday, hitting $3.25. The stock had a trading volume of 4,700 shares, compared to its average volume of 89,115. The firm has a market cap of $100.36, a PE ratio of -1.64 and a beta of 0.46. ProQR Therapeutics has a twelve month low of $2.75 and a twelve month high of $6.90. The company has a current ratio of 5.95, a quick ratio of 6.72 and a debt-to-equity ratio of 0.13.

How to Become a New Pot Stock Millionaire

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by ($0.01). research analysts forecast that ProQR Therapeutics will post -1.74 EPS for the current fiscal year.

Several research analysts recently commented on PRQR shares. Zacks Investment Research raised ProQR Therapeutics from a “sell” rating to a “buy” rating and set a $3.50 target price for the company in a research note on Friday, November 24th. ValuEngine raised ProQR Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, March 2nd. Finally, Chardan Capital reaffirmed a “neutral” rating on shares of ProQR Therapeutics in a research report on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. ProQR Therapeutics currently has an average rating of “Hold” and an average price target of $18.88.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Stock Observer and is owned by of Stock Observer. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at

About ProQR Therapeutics

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein.

Insider Buying and Selling by Quarter for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply